Tustin-based Avid Bioservices inc. (Nasdaq: CDMO) appointed Nicholas Green as its new chief executive officer effective, July 30th.
Green will succeed Rick Hancock who served as interim CEO since May 2019; Hancock will remain on the board of directors following the change of leadership.
“I thoroughly enjoyed my role as the interim president and CEO of Avid and am proud of what the company has achieved,” Hancock said in a press release.
Green recently served as president and CEO of Canada-based Therapure Biopharma. Prior to that, he was managing director of Nipa Laboratories Ltd., and headed the life science division of Clariant International Ltd. in the USA as well as served as president and CEO of Rhodia Pharma Solutions Ltd.
Avid is a dedicated contract development and manufacturing organization specializing in biopharmaceuticals. The company had a $311 million market cap at press time and was trading at $5.62 a share.
